Modality
Gene Therapy
MOA
EZH2i
Target
TIGIT
Pathway
Epigenetic
NSCLCCTCLIgAN
Development Pipeline
Preclinical
~Oct 2018
→ ~Jan 2020
Phase 1
~Apr 2020
→ ~Jul 2021
Phase 2
~Oct 2021
→ ~Jan 2023
Phase 3
Apr 2023
→ Nov 2025
Phase 3Current
NCT04138661
979 pts·CTCL
2023-04→2025-11·Terminated
979 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-11-085mo agoPh3 Readout· CTCL
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P3
Termina…
Catalysts
Ph3 Readout
2025-11-08 · 5mo ago
CTCL
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04138661 | Phase 3 | CTCL | Terminated | 979 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| Miritinib | Neurocrine | Phase 3 | TIGIT | |
| UTH-9370 | United Therapeutics | NDA/BLA | TIGIT |